Page last updated: 2024-11-07

quadazocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Quadazocine is a synthetic opioid analgesic. It is a benzomorphan derivative that binds to the kappa opioid receptor, with some affinity for the mu opioid receptor. Quadazocine was initially studied for its potential as an analgesic and antitussive agent. However, it has been found to have several adverse effects, including dysphoria and hallucinations, and is not currently used clinically. Research on quadazocine has focused on its pharmacological properties, including its interactions with opioid receptors and its effects on the central nervous system. It has also been studied for its potential therapeutic applications, such as in the treatment of pain, anxiety, and addiction.'

quadazocine: RN given refers to (2 alpha,6 alpha,11S*)-(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115077
SCHEMBL ID990529
MeSH IDM0109859

Synonyms (10)

Synonym
(-)-win 44,441
(-)-quadazocine
gtpl1633
quadazocine
69924-29-4
SCHEMBL990529
1-cyclopentyl-5-(8-hydroxy-3,6,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-11-yl)pentan-3-one
DTXSID30990187
Q7268283
1-cyclopentyl-5-[(1s,9r)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-13-yl]pentan-3-one

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects of the kappa opioid agonists, spiradoline (U62,066), enadoline (CI-977) and U69,593, were examined alone and in combination with the opioid antagonists quadazocine and beta-funaltrexamine in squirrel monkeys that responded under a schedule of shock titration."( Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Dykstra, LA; Pitts, RC, 1994
)
0.49

Dosage Studied

ExcerptRelevanceReference
" The opioid antagonist, quadazocine, produced dose-dependent, parallel shifts to the right in the alfentanil dose-response curve."( Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis.
Bertalmio, AJ; Woods, JH, 1989
)
0.58
" Cumulative dose-response curves were determined by infusing increasing drug doses at 60 min intervals over 290 min."( The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative-dosing procedures.
Bowen, CA; Kelly, M; Mello, NK; Negus, SS, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (81)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (51.85)18.7374
1990's32 (39.51)18.2507
2000's7 (8.64)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]